Monitor the 2026 proxy fight as DOMA could push for strategic changes; upcoming clinical data in 2026 may serve as key catalysts. Share repurchases and margin expansion support fundamentals, but no immediate financial impact from the board nomination.
Price Chart
Executive Summary
Pacira BioSciences responded to an activist investor, DOMA Perpetual Capital Management, which has nominated three director candidates for election at the 2026 Annual Meeting. The company reaffirmed its strategic focus on the 5x30 growth plan, highlighted progress including 6.2% EXPAREL volume growth, record gross margins, and pipeline advancements, and emphasized ongoing shareholder engagement. No shareholder action is required at this time.
Key Financial Metrics
Key Facts
- DOMA Perpetual Capital Management nominated three director candidates for Pacira's 2026 Annual Meeting.
- Pacira reiterated progress on its 5x30 strategy, including 6.2% year-over-year EXPAREL volume growth in 2025 (up from 3.6% in 2024).
- Treated 2.5 million patients in 2025, on track toward 3 million annually by 2030.
- GAAP gross margin reached 79% in 2025 (up from 76% in 2024); non-GAAP gross margin was 81%.
- Company executed $150 million in share repurchases in 2025, reducing shares outstanding from 47 million to 41 million.
- Pipeline advances include upcoming 2026 data readouts for ZILRETTA in shoulder OA, iovera in spasticity, and PCRX-201 in knee OA.
- Board has engaged with DOMA 12 times since CEO Frank Lee joined in January 2024; no new strategic insights provided by DOMA.
Financial Impact
Improved gross margins and $150M in share repurchases reduced share count by 12.8%, supporting per-share value. No material near-term P&L impact from governance developments.
Risk Factors
- Potential for increased shareholder activism if operational execution or stock performance lags.
- Clinical trial setbacks in 2026 could disrupt positive momentum despite strong commercial performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254181 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $25.58 $26.60 | ▲ +3.99% | ▲ +3.39% | $25.21 (−1.45%) |
Jul 22, 2026 10w ago | Press Release | $25.59 $24.36 | ▼ −4.81% | ▼ −7.70% | $25.21 (−1.48%) |
Jun 30, 2026 13w ago | 8-K | $25.37 $26.47 | ▲ +4.34% | ▲ +5.36% | $25.21 (−0.63%) |
Jun 13, 2026 15w ago | Insider Cluster | $22.74 $25.54 | ▲ +12.31% | ▲ +13.06% | $25.21 (+10.86%) |
Jun 4, 2026 17w ago | DEFA14A | $22.75 $25.59 | ▲ +12.48% | ▲ +10.62% | $25.21 (+10.81%) |
Jun 4, 2026 17w ago | 144 | $22.67 $25.39 | ▲ +12.00% | ▲ +13.37% | $25.21 (+11.20%) |
Jun 1, 2026 17w ago | DEFA14A | $22.25 $25.03 | ▲ +12.49% | ▲ +14.06% | $25.21 (+13.30%) |
May 27, 2026 18w ago | DEFA14A | $23.68 $25.24 | ▲ +6.59% | ▲ +9.73% | $25.21 (+6.46%) |
May 26, 2026 18w ago | DEFA14A | $24.04 $24.37 | ▲ +1.37% | ▲ +3.27% | $25.21 (+4.87%) |
May 20, 2026 19w ago | DEFA14A | $23.48 $22.72 | ▼ −3.24% | ▼ −3.57% | $25.21 (+7.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access